Furthermore, in the clinic, it remains unclear whether patients with tumours harbouring ATM alterations would benefit from DDR inhibitor treatments, particularly as monotherapy, and importantly, there is no generally accepted best strategy to define ATM deficiency for patient selection. The gene discussed is ATM; the disease is neoplasm.